Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
Diagnostics
In Vitro Diagnostics
Return to: MDBR Home | Diagnostics | In Vitro Diagnostics

Almac Diagnostics partners with ArcherDX

Published 06 October 2016

Almac Group's Diagnostics business has announced its partnership with ArcherDX to provide FusionPlex and VariantPlex NGS assays as part of their CDx partnership solutions.

ArcherDX, the leader in NGS-based fusion detection assays and software, has also approved Almac Diagnostics as a Certified Service Provider (CSP) of Archer® NGS assays.

This agreement further establishes Almac Diagnostics as a trusted partner providing scientific and technological excellence globally.

Almac Diagnostics, the personalised medicine business unit of the Almac Group, partners with Biopharma on the discovery, development and commercialisation of diagnostic tests including companion diagnostics.  It also has an internal portfolio of both prognostic and predictive assays in development across a wide range of disease areas.

As an Archer Certified Service Provider, Almac Diagnostics will leverage their CLIA-certified lab to include Archer FusionPlex® and VariantPlex™ assays in their service offering. About becoming an Archer CSP, Michael Sloan, VP Commercial Operations at Almac Diagnostics, stated, "Archer assays will not only enable us to offer targeted sequencing panels across a wide range of malignancies, but they give us the ability to customise gene panels based on our partners' needs."

Jason Myers, PhD, CEO at ArcherDX, added, "Almac Diagnostics has a strong support network as part of the Almac Group, which gives them the ability to provide clinical services beyond the UK. Because clinical development is a global need, we're excited that Almac Diagnostics can offer ArcherDX NGS assays for international drug and CDx development and clinical support."

ArcherDX addresses the bottlenecks associated with using NGS in translational research by offering a robust platform for targeted sequencing applications.

By combining proprietary Anchored Multiplexed PCR (AMP™) chemistry and easy-to-use, lyophilized reagents, Archer NGS assays generate highly enriched sequencing libraries to detect gene fusions, point mutations, CNVs and RNA abundance.

Complemented by the Archer suite of bioinformatics software, ArcherDX technology dramatically enhances complex mutation identification and discovery. 



Source: Company Press Release